STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

8,651

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 8, 2016

Study Completion Date

December 5, 2016

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

rVSVΔG-ZEBOV

The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).

Trial Locations (5)

Unknown

College of Medicine and Allied Health Sciences (COMAHS), Freetown

Bombali, Bombali District

Port Loko, Port Loko District

Tonkolili, Tonkolili District

Western Area Rural, Western Area District

All Listed Sponsors
collaborator

University of Sierra Leone

OTHER

collaborator

Ministry of Health and Sanitation, Sierra Leone

OTHER_GOV

collaborator

Department of Health and Human Services

FED

collaborator

eHealth Africa

OTHER

lead

Centers for Disease Control and Prevention

FED

NCT02378753 - STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) | Biotech Hunter | Biotech Hunter